Efficacy of single-dose mebendazole, polymorphic forms A and C, in the treatment of hookworm and Trichuris infections (1993)

Peer-Reviewed Study · Charoenlarp P; Waikagul J; Muennoo C; Srinophakun S; Kitayaporn D · December 1993

Charoenlarp P et al., 1993-12: A randomised placebo-controlled trial in 958 Thai schoolchildren showing that 300 mg of polymorph A was no better than placebo against hookworm and Trichuris, while polymorph C worked at the same dose. It is the human clinical proof that the crystal form, not just the molecule, determines whether mebendazole works.

The efficacy of single dose 300 mg polymorph A was not different from that of the placebo control (alpha = 0.05) in both infections.

abstract

Charoenlarp P et al., 1993-12: A randomised placebo-controlled trial in 958 Thai schoolchildren showing that 300 mg of polymorph A was no better than placebo against hookworm and Trichuris, while polymorph C worked at the same dose. It is the human clinical proof that the crystal form, not just the molecule, determines whether mebendazole works. Study type: randomised controlled trial with placebo and active controls. N=958 children, seven treatment groups. Country: Thailand (primary schools in southern Thailand; Mahidol University). Dose: single 300 mg polymorph A; single 300 mg polymorph C; single 500 mg polymorph C; standard control 100 mg polymorph C twice daily for 3 days; placebo. Route: oral. Funder/conflicts: not stated in the abstract (full text not read). Manufacturer: not stated in the abstract. Comparator: placebo and standard-dose control. Outcome: egg reduction rates and cure rates. This is direct human evidence that polymorph identity changes efficacy – the mechanism behind the 2015 mouse findings in MBA-35. Study type: randomized trial.